CN100344318C - Medicine for treating apoplectic sequel and prepn. thereof - Google Patents
Medicine for treating apoplectic sequel and prepn. thereof Download PDFInfo
- Publication number
- CN100344318C CN100344318C CNB2005101259739A CN200510125973A CN100344318C CN 100344318 C CN100344318 C CN 100344318C CN B2005101259739 A CNB2005101259739 A CN B2005101259739A CN 200510125973 A CN200510125973 A CN 200510125973A CN 100344318 C CN100344318 C CN 100344318C
- Authority
- CN
- China
- Prior art keywords
- rhizoma
- medicine
- carapax
- radix
- fine powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 43
- 229940079593 drug Drugs 0.000 title claims description 16
- 208000006011 Stroke Diseases 0.000 claims abstract description 21
- 206010008190 Cerebrovascular accident Diseases 0.000 claims abstract description 20
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 10
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 10
- 235000008434 ginseng Nutrition 0.000 claims abstract description 10
- 241000255791 Bombyx Species 0.000 claims abstract description 9
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 241000305492 Gastrodia Species 0.000 claims abstract description 3
- 239000000843 powder Substances 0.000 claims description 16
- 241001550206 Colla Species 0.000 claims description 10
- 241000209020 Cornus Species 0.000 claims description 10
- 241000208340 Araliaceae Species 0.000 claims description 9
- 241000272074 Bungarus Species 0.000 claims description 9
- 241000237903 Hirudo Species 0.000 claims description 9
- 241000237636 Pheretima Species 0.000 claims description 9
- 241000522620 Scorpio Species 0.000 claims description 9
- 239000009490 scorpio Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- 230000003285 pharmacodynamic effect Effects 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 5
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 241000272060 Elapidae Species 0.000 abstract 1
- 241000545744 Hirudinea Species 0.000 abstract 1
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 241000239226 Scorpiones Species 0.000 abstract 1
- 241000270666 Testudines Species 0.000 abstract 1
- 241000270708 Testudinidae Species 0.000 abstract 1
- 210000003056 antler Anatomy 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 241001233061 earthworms Species 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 239000003292 glue Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 17
- 239000008280 blood Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 230000010354 integration Effects 0.000 description 10
- 210000003734 kidney Anatomy 0.000 description 10
- 206010019468 Hemiplegia Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 6
- 206010013952 Dysphonia Diseases 0.000 description 5
- 208000002173 dizziness Diseases 0.000 description 5
- 238000002651 drug therapy Methods 0.000 description 5
- 210000003127 knee Anatomy 0.000 description 5
- 230000001914 calming effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 208000009205 Tinnitus Diseases 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 231100000886 tinnitus Toxicity 0.000 description 3
- 241000721047 Danaus plexippus Species 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101001054842 Homo sapiens Leucine zipper protein 4 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 102100026910 Leucine zipper protein 4 Human genes 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 201000002676 cerebral atherosclerosis Diseases 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000009519 fu-yuan Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 208000026473 slurred speech Diseases 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Abstract
The present invention discloses a medicine for treating sequelae of apoplexy, which is prepared from medicinal raw materials of ginseng, antler glue, tortoise, wolfberry fruits, turtle shells, leech, chuanxiong rhizome, rhubarb, haws, earthworms, scorpions, multibanded kraits, gastrodia tuber, bombyx batryticatus and borneol. The present invention also relates to a method for preparing the medicinal raw materials into capsulated agents.
Description
Technical field
The present invention relates to medicine for the treatment of apoplexy sequela and preparation method thereof.
Background technology
Apoplexy also claims cerebrovascular, comprises cerebral infarction and hemorrhagic apoplexy.One of characteristics of apoplexy are its high disability rates.The patient that those save one's life through early stage treatment, often stay serious sequela, modal is completeness and imperfection hemiplegia, hemiplegia, facial hemiparalysis, slurred speech, contracture of the limbs, numb limbs and tense tendons, swollen foot and knee, gatism, bones and muscles pain etc.These sequela are greatly endangering patient's life quality.
Also do not treat the specific drug of apoplexy sequela in current medical circle.The medicine of the multiple treatment apoplexy sequela of clinical practice at present, its curative effect is far from satisfactory, and is starved of to excavate medicine easy to use, better efficacy.Chinese medicine is in characteristic and advantage that oneself is arranged aspect the treatment apoplexy sequela, and some having occurred respectively characteristics, and the Chinese patent medicine of certain curative effect is arranged.But these shortcomings that Chinese patent medicine ubiquity curative effect is lower, onset is slower.The inventor constantly carries out the research and the exploration of Chinese medicine apoplexy sequela in medical practice for many years, obtained the technological achievement that comprises the present invention.
Summary of the invention
The object of the present invention is to provide a kind of medicine with the Chinese medicine composition preparation, its manufacture method is easy, economical, and the treatment apoplexy sequela is had sure effect.
Medicine of the present invention is to be made by the pharmacodynamic raw materials medicine of following weight proportion:
Radix Ginseng 45～50 Colla cornus cervis 20～25 Carapax Et Plastrum Testudiniss 33～38 Fructus Lycii 33～38
Carapax Trionycis 33～38 Hirudos 45～50 Rhizoma Chuanxiongs 33～38 Radix Et Rhizoma Rhei 13～18
Fructus Crataegi 25～30 Pheretimas 25～30 Scorpios 25～30 Bungarus Parvus 45～50
Rhizoma Gastrodiae 33～38 Bombyx Batryticatus 20～25 Borneolum Syntheticums 5～10.
Above-mentioned raw materials medicine optimum weight proportioning is,
Radix Ginseng 48 Colla cornus cervis 22 Carapax Et Plastrum Testudiniss 36 Fructus Lycii 36 Carapax Trionycis 36 Hirudos 48
Rhizoma Chuanxiong 36 Radix Et Rhizoma Rhei 15 Fructus Crataegis 28 Pheretimas 28 Scorpios 28
Bungarus Parvus 48 Rhizoma Gastrodiaes 36 Bombyx Batryticatus 22 Borneolum Syntheticums 8.
Medicine of the present invention can be made into multiple dosage form alleged on the pharmaceutics with above crude drug, and optimum dosage form is a capsule.It is as follows to make capsular process:
Fructus Lycii, Fructus Crataegi are decocted the back and filter, be condensed into thick paste; To be blended in the thick paste after the Colla cornus cervi molten; Radix Ginseng, Radix Et Rhizoma Rhei, Rhizoma Gastrodiae and Bungarus Parvus are ground into coarse powder, mix thoroughly with above-mentioned thick paste, drying is ground into fine powder again; Carapax Et Plastrum Testudinis, Carapax Trionycis, Hirudo, Pheretima, Scorpio, Bombyx Batryticatus, Rhizoma Chuanxiong seven medicine pulverize separately are become fine powder; Borneolum Syntheticum is ground into fine powder; With above steps gained fine powder mixed grinding, sieve, divide encapsulated.
The present invention is directed to apoplexy is liver-wind stirring up internally, the hot-tempered system of nothing more, and bleeding resulting from adverse flow of QI, upper punch brain arteries and veins covers the mechanism of filling in the brain key and falling ill, the Therapeutic Principle who gets vital energy benefiting and the kidney invigorating, blood circulation promoting and blood stasis dispelling, calming wind and dredging collateral.Prescription is with the Radix Ginseng strongly invigorating primordial QI, and element culturing fixed folder is with being monarch drug; The Colla cornus cervi invigorating the liver and kidney, benefiting essence-blood; The Carapax Et Plastrum Testudinis nourishing YIN for suppressing the hyperactive YANG, replenishing kidney and strengthening bone, the reinforcing the heart of nourishing blood; Fructus Lycii nourishing kidney lung moistening tonifying liver; The Carapax Trionycis nourishing YIN for suppressing the hyperactive YANG, hard masses softening and resolving.This, the Colla cornus cervi YANG invigorating, Carapax Et Plastrum Testudinis, Fructus Lycii, Carapax Trionycis YIN nourishing, so-called Yang is originated from yin, yin derived from yang, tonifying both YIN and YANG, Yin-nourishing and Yang-supporting is all ministerial drug, collaborative monarch drug vital energy benefiting and the kidney invigorating, element culturing fixed folder.Assistant is with the Hirudo removing blood stasis; Radix Et Rhizoma Rhei is attacked long-pending relieving constipation, removing blood stasis is active; The mountain is picked up promoting digestion and removing stagnation, promoting blood circulation to remove blood stasis with the fingers; Rhizoma Chuanxiong blood-activating and qi-promoting, wind-expelling pain-stopping; Pheretima, Scorpio promoting blood circulation to remove obstruction in the collateral, relieving spasm by subduing liver-wind; Bungarus Parvus is got and walks internal organs in it, outer thorough skin, the deep wind of searching, active arresting convulsion.More than all medicine blood circulation promoting and blood stasis dispelling, calming wind and dredging collateral is all adjuvant drug.Borneolum Syntheticum fragrance is hot to loose, and the through sick institute of all medicines is drawn in the refreshment of having one's ideas straightened out, and is to think to make.Take a broad view of full side, with element culturing fixed folder, vital energy benefiting and the kidney invigorating Zhi Qiben, control its mark with blood circulation promoting and blood stasis dispelling, calming wind and dredging collateral, giving consideration to both the incidental and fundamental is played vital energy benefiting and the kidney invigorating altogether, blood circulation promoting and blood stasis dispelling, the merit of calming wind and dredging collateral.
The good efficacy of Drug therapy apoplexy sequela of the present invention is confirmed in following experimental example.
Experimental example Drug therapy hemiplegia of the present invention is levied 100 routine clinical observation on the therapeutic effect
For curative effect and the safety of estimating Drug therapy apoplexy sequela of the present invention, carry out clinical verification by Henan Province institute of traditional Chinese medicine, Henan Prov. Inst. of Chinese Medicine ﹠ Pharmacology, No.1 Hospital Attached to He'nan Traditional Chinese Medical College, final report is as follows.
Data and method
One. physical data
Observing patient's 130 examples altogether, all is stroke rehabilitation phase patient.Test group 100 examples wherein, matched group 30 examples.Sex: male 67 examples in the test group, women 33 examples; Male 17 examples in the matched group, women 13 examples.Age: test group 62.14 ± 5.94 years old; Matched group 62.81 ± 5.39 years old.The course of disease: test group average course of disease 5.24 ± 2.01 years; Matched group average course of disease 5.60 ± 1.26 years.Learn check by statistics, age, the course of disease, severity extent and neurological functional deficit etc. all have comparability between two groups.
Two, case is selected
1. Western medicine diagnose standard: often under rest state, fall ill; Great majority do not have obviously headache and vomiting; Morbidity can be slower, progress gradually how, or be stage and carry out, how relevant with cerebral atherosclerosis, also be found in arteritis, hematopathy etc.; General morbidity back clear or slight obstacle of consciousness on the 1st～2; Arterial system sings and symptoms at the bottom of internal carotid artery system and/or the vertebra is arranged; Waist is worn cerebrospinal fluid generally should not contain blood; CT examination is found cerebral location of lesions.
2. tcm diagnosis standard
1. primary symptom: hemiplegia, crooked mouth and tongue, the expression unconsciousness, the stiff tongue speech is not smoothgoing or in silence, hemianesthesia; 2. Acute onset; 3. sick sending out has inducement, before sending out premonitory symptom arranged; 4. the age is more than 40 years old.
Have more than the primary symptom binomial, can determine diagnosis in conjunction with one of remainder.
3. Chinese medical discrimination
Blood stagnancy due to deficiency of QI, deficiency of kidney essence card: hemiplegia, crooked mouth and tongue, dysphonia, numb hand and foot, dizzy ear toot, soreness of the waist and knees, dimly pale tongue, thin white fur of tongue or white greasy, deep-thready pulse.
Main symptom: 1. hemiplegia; 2. waist knee joint disease is soft;
Inferior card: 1. crooked mouth and tongue; 2. dysphonia; 3. numb hand and foot; 4. dizziness and tinnitus; 5. dimly pale tongue, deep-thready pulse.
Dialectical requirement
I. possess main symptom 1. 2. the person promptly belong to assertive evidence;
II. possessing main symptom 1. reaches time two persons of card and promptly belongs to assertive evidence.
III. possess main symptom 2. reach time card 1. 2. the person promptly belong to assertive evidence.
4. the state of an illness and the course of disease: every vital signs and nervous system signs are stable, and morbidity is more than 2 weeks.
Two, case standard
1. include the case standard in: meet diagnosis of apoplexy cerebral thrombosis and Chinese medical discrimination, the state of an illness and course of disease standard person, can include the test case in.
2. get rid of the case standard: 1. transient ischemic attack; 2. confirm on inspection by the cerebral tumor, cerebral trauma, cerebral parasitosis, dysbolismus, rheumatic heart disease, coronary heart disease and other heart disease merge atrial fibrillation, the person that causes the cerebral embolism; 3. more than 80 years old, gestation or women breast-feeding their children are to this medicine allergy sufferers; 4. be associated with serious primary disease such as liver, kidney, hemopoietic system and hormonal system, the psychotic; 5. all standards of including in that do not meet, not medication in accordance with regulations can't be judged that curative effect or data are not congruent to affect the treatment or safety judgement person.
3. eliminate the case standard: Chinese medical discrimination ownership extreme hyperactivity of the liver-yang, wind-fire upper harassing syndrome; Wind-phlegm blood stasis, numbness resistance venation disease, real, the syndrome of wind-phlegm invading upward of the hot internal organs of expectorant.
Four, grouping contrast
This test is divided into two groups, adopts design at random, and two groups of cases do not have marked difference at aspects such as sex, age, the state of an illness, body constitution, have comparability.
Five, medicine and usage
Test group is taken the capsule of making by the embodiment of the invention 1, each 4, every day 3 times.Matched group is taken the PIANTAN FUYUAN WAN that Tongrentang Pharmaceutical Factory, Beijing produces, each 4 balls, every day 3 times.30 days is a course of treatment, stop using during taking its antagonism or cooperative drug.
Six, observation index
1. safety observation: 1. general physical examination project; 2. blood, urine, just routine test; 3. the heart, liver, kidney function test; 4. hemostasis detects with coagulation function, comprises PT, TT, APTT, FIB.
2. curative effect observation: 1. clinical symptoms is improved degree, disappearance natural law.2. nervous system body shape.3. Cranial Computed Tomography scanning.
Seven, curative effect determinate standard
Change and treatment integration judgement curative effect according to symptom, sign.The apoplexy point system, the starting point branch is no more than 18 fens, and curative effect integration evaluation formula is:
Curative effect integration [integration before (integration one treatment back integration before the treatment) ÷ treatment] * 100%
Recovery from illness: symptom and sign disappear, and can live on one's own life substantially; Or integration 〉=85%.
Produce effects: symptom and sign take a turn for the better, can cane walking or take care of oneself substantially; Or integration 〉=50%.
Effectively: symptom and sign partly disappear, and can stand under other people help, and can't take care of oneself; Or integration 〉=20%.
Invalid: symptom and sign no change; Or integration＜20%.
The result
One. medicine of the present invention the results are shown in Table 1 to apoplexy main symptom and traditional Chinese medical science disease efficacy analysis.
Choose 5 syndromes of apoplexy, comprise that hemiplegia, crooked mouth and tongue, dysphonia, dizziness and tinnitus, soreness of the waist and knees etc. carry out statistical procedures, the treatment group is significantly improved to preceding 5 after the medication, and matched group also has improvement, there were significant differences between two groups (P＜0.01), and clinical syndrome the be significantly improved effect of medicine of the present invention to blood stagnancy due to deficiency of QI, deficiency of kidney essence card is described.
Table 1 liang group doing well,improving situation is (example) relatively
| Symptom | Group | The example number | Disappear | Alleviate | No change |
| Hemiplegia | The treatment group | 94 | 16* | 49* | 29 |
| Matched group | 28 | 3 | 9 | 16 | |
| Crooked mouth and tongue | The treatment group | 85 | 19* | 60* | 6* |
| Matched group | 26 | 8 | 14 | 4 | |
| Dysphonia | The treatment group | 68 | 14* | 48* | 6* |
| Matched group | 14 | 2 | 9 | 3 | |
| Dizziness and tinnitus | The treatment group | 91 | 51* | 33* | 7* |
| Matched group | 19 | 8 | 9 | 6 | |
| Soreness of the waist and knees | The treatment group | 96 | 80* | 10* | 6* |
| Matched group | 29 | 6 | 20 | 3 |
Annotate: compare * P＜0.01 with matched group.
Two, clinical efficacy evaluation the results are shown in Table 2.
Table 2 liang group curative effect is [example (%)] relatively
| Group | The example number | Recovery from illness | Produce effects | Effectively | Invalid | Total effective rate |
| The treatment group | 100 | 46(46.00) | 26(26.00) | 10(10.00) | 18(18.00) | 82.00 |
| Matched group | 30 | 10(33.33) | 6(20.00) | 2(6.67) | 12(40.00) | 60.00 |
Annotate: compare * P＜0.01 with matched group
Drug therapy patient's cure rate 46% of the present invention, total effective rate 82.0% obviously is better than matched group.
Three, medicine of the present invention is to the influence of cranium CT
The treatment group is taken medicine and was checked cranium CT28 example in back 1 month, and the infarct size person of dwindling 6 examples account for 21.43%.This 6 routine patients clinical symptom and sign also have clear improvement, and improve with cranium CT to be consistent.
Four, safety is observed
Do not find in the process of the test that medicine of the present invention has obvious toxic-side effects.PT, TT measure the treatment group has obvious prolongation (P＜0.05) than matched group, but all in safety range.Do not have significant change between two groups of APTT and F1B, all fluctuate in normal value.
In a word, Drug therapy apoplexy sequela total effective rate of the present invention is 82.00%, and cure rate is 46%, to hemiplegia, crooked mouth and tongue, dysphonia, dizzy ear toot, the symptom effect of having clear improvement such as soreness of the waist and knees, cranium CT shows certain curative effect, does not find toxicity.
The specific embodiment
The invention will be further described by the following examples.
Embodiment takes by weighing Radix Ginseng 48g, Colla cornus cervi 22g, Carapax Et Plastrum Testudinis 36g, Fructus Lycii 36g, Carapax Trionycis 36g, Hirudo 48g, Rhizoma Chuanxiong 36g, Radix Et Rhizoma Rhei 15g, Fructus Crataegi 28g, Pheretima 28g, Scorpio 28g, Bungarus Parvus 48g, Rhizoma Gastrodiae 36g, Bombyx Batryticatus 22g, Borneolum Syntheticum 8g.
Fructus Lycii, Fructus Crataegi are decocted with water three times, decocted 2 hours for the first time, second and third time respectively decocted 1 hour, and collecting decoction filters, and is condensed into thick paste; Colla cornus cervi is blended in the thick paste after with an amount of decocting liquid molten; Radix Ginseng, Radix Et Rhizoma Rhei, Rhizoma Gastrodiae and Bungarus Parvus are ground into coarse powder, mix thoroughly with above-mentioned thick paste, drying is ground into fine powder again; With all the other crude drug Carapax Et Plastrum Testudiniss, Carapax Trionycis, Hirudo, Pheretima, Scorpio, Bombyx Batryticatus, Rhizoma Chuanxiong power are broken into fine powder, and Borneolum Syntheticum is ground into fine powder.With above-mentioned each fine powder mixed grinding, sieve, divide encapsulatedly, make 1000.Each oral 3～5 of adult patients, every day 2～4 times.
Claims (3)
1. a medicine for the treatment of apoplexy sequela is characterized in that, pharmacodynamic raw materials and the weight proportion thereof of making it are:
Radix Ginseng 45～50 Colla cornus cervis 20～25 Carapax Et Plastrum Testudiniss 33～38 Fructus Lycii 33～38
Carapax Trionycis 33～38 Hirudos 45～50 Rhizoma Chuanxiongs 33～38 Radix Et Rhizoma Rhei 13～18
Fructus Crataegi 25～30 Pheretimas 25～30 Scorpios 25～30 Bungarus Parvus 45～50
Rhizoma Gastrodiae 33～38 Bombyx Batryticatus 20～25 Borneolum Syntheticums 5～10.
2. medicine according to claim 1 is characterized in that, the weight proportion of used pharmacodynamic raw materials is:
Radix Ginseng 48 Colla cornus cervis 22 Carapax Et Plastrum Testudiniss 36 Fructus Lycii 36 Carapax Trionycis 36 Hirudos 48
Rhizoma Chuanxiong 36 Radix Et Rhizoma Rhei 15 Fructus Crataegis 28 Pheretimas 28 Scorpios 28
Bungarus Parvus 48 Rhizoma Gastrodiaes 36 Bombyx Batryticatus 22 Borneolum Syntheticums 8.
3. the preparation method of claim 1 or 2 described medicines is characterized in that, Fructus Lycii, Fructus Crataegi are decocted the back and filter, and is condensed into thick paste; To be blended in the thick paste after the Colla cornus cervi molten; Radix Ginseng, Radix Et Rhizoma Rhei, Rhizoma Gastrodiae and Bungarus Parvus four medicated powder are broken into coarse powder, mix thoroughly with above-mentioned thick paste, drying is ground into fine powder again; Carapax Et Plastrum Testudinis, Carapax Trionycis, Hirudo, Pheretima, Scorpio, Bombyx Batryticatus, Rhizoma Chuanxiong seven medicine pulverize separately are become fine powder; Borneolum Syntheticum is ground into fine powder; With above steps gained fine powder mixed grinding, sieve, divide encapsulated.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101259739A CN100344318C (en) | 2005-12-01 | 2005-12-01 | Medicine for treating apoplectic sequel and prepn. thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101259739A CN100344318C (en) | 2005-12-01 | 2005-12-01 | Medicine for treating apoplectic sequel and prepn. thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1833711A CN1833711A (en) | 2006-09-20 |
| CN100344318C true CN100344318C (en) | 2007-10-24 |
Family
ID=37001701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005101259739A Active CN100344318C (en) | 2005-12-01 | 2005-12-01 | Medicine for treating apoplectic sequel and prepn. thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100344318C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105727054A (en) * | 2016-04-29 | 2016-07-06 | 李宝娟 | Traditional Chinese medicine preparation for treating sequela of apoplexy |
| CN106581518A (en) * | 2017-02-07 | 2017-04-26 | 郑法海 | Traditional Chinese medicine composition for treating stroke, hemiparalysis and sequelae of stroke and hemiparalysis |
| CN111920921B (en) * | 2020-09-14 | 2022-03-08 | 河南中医药大学 | Seven-worm compound traditional Chinese medicine for treating stroke |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1539447A (en) * | 2003-04-27 | 2004-10-27 | 王振廷 | Medicated rehabilitation wine for treating premonitory apoplexy, sequela of apoplexy and obastrcution of qi in chest |
-
2005
- 2005-12-01 CN CNB2005101259739A patent/CN100344318C/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1539447A (en) * | 2003-04-27 | 2004-10-27 | 王振廷 | Medicated rehabilitation wine for treating premonitory apoplexy, sequela of apoplexy and obastrcution of qi in chest |
Non-Patent Citations (1)
| Title |
|---|
| 近年中医药治疗中风后遗症进展 胡怀强，河南中医学院学报2003，第18卷第6期 2003 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1833711A (en) | 2006-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1857541A (en) | Plaster for treating rheumatism and osteoarthrosis | |
| CN1868535A (en) | Medicine composition for treating rheumatic arthritis and rheumatoid arthritis, and its prepn. method | |
| CN1965996A (en) | Preparation method of Chinese medicinal capsule for treating apoplexy | |
| CN100344318C (en) | Medicine for treating apoplectic sequel and prepn. thereof | |
| CN104524247B (en) | One treats migrainous medical composition and its use | |
| CN1843421A (en) | Rheumatoid disease treating medicine | |
| CN1520862A (en) | Prepared traditional Chinese medicine for apoplexy and obstruction of qi in the chest | |
| CN103585414B (en) | Pharmaceutical composition for treating sciatica and osteoporosis | |
| CN1111054C (en) | Medicine for treating apoplexy and its preparing process | |
| CN102872292B (en) | Traditional Chinese medicine for curing spleen and kidney deficiency type ischemic post-stroke depression | |
| CN1723933A (en) | Traditional Chinese medicine capsule for treating application, and its prodn. method | |
| CN101284108A (en) | Traditional Chinese medicine combination for curing lumbar disease | |
| CN1973876A (en) | Chinese medicine for treating kidney deficiency and its prpen | |
| CN1970067B (en) | Chinese medicinal formulation for treating vertebrae hyperosteogeny, protrusion of intervertebral disc and spinal stenosis | |
| CN1943691A (en) | A Chinese traditional medicinal composition for treatment of osteoporosis and its preparation method | |
| CN1216622C (en) | Ointment for intervertebral disc | |
| CN1201811C (en) | Chinese medicine composition for treating myopia and preparing method thereof | |
| CN115844972B (en) | Navel patch for treating osteoporosis and preparation method thereof | |
| CN115624582B (en) | New prescription for treating knee pain and preparation method and application thereof | |
| CN1562117A (en) | Chinese medicinal preparation for quick bone fracture setting | |
| CN102600251A (en) | Compound rheumatism-rehabilitating composite agent | |
| CN114588242B (en) | Pharmaceutical composition for treating rheumatoid arthritis | |
| CN1544019A (en) | Chinese traditional medicine composition for treating arthralgia syndrome of cervical spondylopathy and its preparation | |
| CN1112191C (en) | Medicine for treating rheumatic arthritis and hyperosteogeny and its preparing process | |
| CN109010682B (en) | Traditional Chinese medicine composition for treating central nervous function damage and warming governor vessel, eliminating turbid pathogen and dredging collaterals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160304 Address after: B western building western street in Qingyang District of Chengdu City, Sichuan province 610000 24 floor Patentee after: Deng Jinyong Address before: 450008 No. 175, Dongming Road, Zhengzhou, Henan Patentee before: Han Qunying |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20161205 Address after: 475000 Henan Kaifeng Jinming Industrial Park Road, No. 9 Patentee after: KAIFENG DASONG PHARMACEUTICAL CO.,LTD. Address before: B western building western street in Qingyang District of Chengdu City, Sichuan Province, 24 floor Patentee before: Deng Jinyong |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210120 Address after: 6 Jianye Road, Xinwei Industrial Park, Weishi County, Kaifeng City, Henan Province Patentee after: Henan Bifu Pharmaceutical Co.,Ltd. Address before: 475000 Minfa Road, Jinming Industrial Park, Kaifeng City, Henan Province Patentee before: KAIFENG DASONG PHARMACEUTICAL Co.,Ltd. |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20240328 Address after: 475000 Minfa Road, Jinming Industrial Park, Kaifeng City, Henan Province Patentee after: KAIFENG DASONG PHARMACEUTICAL CO.,LTD. Country or region after: China Address before: No. 6 Jianye Road, Xinwei Industrial Park, Weishi County, Kaifeng City, Henan Province Patentee before: Henan Bifu Pharmaceutical Co.,Ltd. Country or region before: China |